Zydus launches affordable biosimilar 'Zyrifa' for cancer-related bone complications
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
Subscribe To Our Newsletter & Stay Updated